

Contents

List of contributors	xiii		
About the editors	xvii		
Preface to the seventh edition	xxi		
Preface to the sixth edition	xxiii		
Preface to the fifth edition	xxv		
Preface to the fourth edition	xxvii		
Preface to the third edition	xxix		
Preface to the second edition	xxxi		
Preface to the first edition	xxxiii		
Introduction: Historic perspective (1955–2015)	xxxv		
1. Molecular and genomic methodologies for clinicians	1		
JORDAN A. SHAVIT AND RAJEN J. MODY			
Clinical molecular and genomic methodologies: goals	1		
Methods of genetic analysis	1		
Interpretation of genetic variants obtained from next-generation sequencing	4		
Applications of next-generation sequencing to oncology	4		
Interpreting and evaluating the results from clinical genetic testing	6		
Further reading and references	6		
2. Hematologic manifestations of systemic illness	7		
BRIAN M. DULMOVITS AND LAWRENCE C. WOLFE			
Alterations to red blood cells related to organ-specific pathologies	7		
Alterations to white blood cells related to organ-specific pathologies	12		
Alterations to platelets and coagulation related to organ-specific pathologies	13		
General considerations for the hematologic sequelae of infection	15		
Viral and bacterial illnesses associated with marked hematologic sequelae	15		
Parasitic illnesses associated with marked hematologic sequelae	21		
Hemolytic uremic syndrome	22		
Autoimmune disease	23		
Anemia of inflammation	25		
Nutritional deficiencies and environmental exposures	27		
Marrow infiltrative disorders	28		
Further reading and references	34		
3. Classification and diagnosis of anemia in children and neonates	37		
OMAR NISS AND CHARLES T. QUINN			
Classification and diagnosis	37		
Neonatal anemia	40		
Further reading and references	59		
4. Nutritional anemias	61		
JACQUELYN M. POWERS			
Overview	61		
Iron-deficiency anemia	61		
Megaloblastic anemia	71		
Further reading and references	80		
5. Lymphadenopathy and diseases of the spleen	81		
PHILIP LANZKOWSKY			
Lymphadenopathy	81		
Diseases of the spleen	86		
Further reading and references	89		
6. Bone marrow failure	91		
ADRIANNA VLACHOS, MICHELLE NASH AND JEFFREY M. LIPTON			
Aplastic anemia	91		
Inherited bone marrow failure syndromes	102		
Further reading and references	122		
7. General considerations of hemolytic diseases, red cell membrane, and enzyme defects	125		
LIONEL BLANC AND LAWRENCE C. WOLFE			
Clinical features of hemolytic disease	125		
Laboratory findings	126		
Membrane defects	128		
Paroxysmal nocturnal hemoglobinuria	138		
Enzyme defects	142		
Further reading and references	148		
8. Extracorporeal hemolytic anemia	151		
ANSHUL VAGRECHA AND LAWRENCE C. WOLFE			
Immune hemolytic anemia	151		
Nonimmune hemolytic anemia	158		
Further reading and references	159		

9. Hemoglobinopathies	161	14. Vascular anomalies	341
EUGENE KHANDROS AND JANET L. KWIATKOWSKI		RACHEL KESSEL, FRANCINE BLEI AND IONELA IACOBAS	
Sickle cell disease	161	Introduction	341
Sickle cell trait (heterozygous form, AS)	179	Vascular tumors	341
Hemoglobin C	179	Simple vascular malformations	343
Hemoglobin E	180	Diagnostic work-up for vascular lesions	344
Unstable hemoglobins	180	Management	347
Thalassemias	180	Evaluation and monitoring of a vascular hepatic tumor	348
Further reading and references	191	Vascular anomaly syndromes	350
		Further reading and references	356
10. Primary and secondary erythrocytosis	193	15. Histiocytic disorders	357
TSEWANG TASHI AND JOSEF T. PRCHAL		OLIVE S. ECKSTEIN AND CARL E. ALLEN	
Erythrocytosis or polycythemia	193	Introduction	357
Primary erythrocytosis	195	Langerhans cell histiocytosis	357
Secondary erythrocytosis	197	Other histiocytic disorders	369
Diagnostic approach to erythrocytosis	203	Hemophagocytic lymphohistiocytosis (hemophagocytic syndromes)	371
Further reading and references	204	Further reading and references	374
11. Disorders of white blood cells	207	16. Lymphoproliferative disorders	377
KELLY WALKOVICH AND JAMES A. CONNELLY		DAVID T. TEACHEY	
Leukocytosis	207	Angioimmunoblastic lymphadenopathy with dysproteinemia	377
Leukopenia	208	Small lymphocytic infiltrates of the orbit and conjunctiva (ocular adnexal lymphoid proliferation, pseudolymphoma, benign lymphoma, atypical lymphocytic infiltrates)	378
Neutrophil disorders	208	Angiocentric immunolymphoproliferative disorders	378
Monocytes disorders	217	Castleman disease (angiofollicular lymph node hyperplasia, benign giant lymph node hyperplasia, angiomatous lymphoid hamartoma)	379
Eosinophil disorders	220	Epstein-Barr virus-associated Lymphoproliferative disorders in immunocompromised individuals	380
Basophil disorders	226	X-linked lymphoproliferative syndrome	385
Lymphocyte disorders	228	Autoimmune lymphoproliferative syndrome	386
Dedication	235	Lymphomatoid papulosis in children	389
Further reading and references	235	Further reading and references	390
12. Disorders of platelets	237	17. Myelodysplastic syndromes and myeloproliferative disorders	391
CATHERINE MCGUINN AND JAMES B. BUSSEL		INGA HOFMANN, NOBUKO HIJIYA AND MOHAMED TAREK ELGHETANY	
Thrombocytopenia in the newborn	237	Myelodysplastic syndromes	391
Inherited thrombocytopenias	248	Myeloid proliferations in children with Down syndrome (DS)	398
Immune thrombocytopenic purpura	257	Juvenile myelomonocytic leukemia	398
Other causes of thrombocytopenia	265	Myeloproliferative neoplasms	403
Thrombocytosis	270	Further reading and references	409
Qualitative platelet disorders	272	18. Acute lymphoblastic leukemia	413
Inherited vascular and connective tissue disorders	280	PALLAVI M. PILLAI AND WILLIAM L. CARROLL	
Nonthrombocytopenic purpura	281	Incidence of ALL	413
Laboratory evaluation of platelets and platelet function	282	Etiology	413
Further reading and references	284		
13. Disorders of coagulation	287		
SUSMITA N. SARANGI AND SUCHITRA S. ACHARYA			
Hemostatic disorders	287		
Acquired coagulation factor disorders	297		
Inherited coagulation factor disorders	299		
Thrombotic disorders	315		
Antithrombotic therapy	332		
Further reading and references	339		

Clinical features of ALL	414	Staging	476
Diagnosis	416	Prognosis	476
Classification	417	Management	477
Cytogenetics and molecular genetics of ALL	420	Non-Hodgkin Lymphoma Subtypes	479
Prognostic factors	421	Further reading and references	482
Treatment	422		
Infant leukemia	429	22. Central nervous system tumors	485
Philadelphia-positive ALL	430	DEREK HANSON AND MARK P. ATLAS	
Ph-like ALL	431	Pathology	485
Down syndrome and ALL	431	Clinical manifestations	486
Relapse in children with ALL	431	Diagnostic evaluation	488
Immunotherapy for ALL	433	Treatment	490
Central nervous system relapse	434	Specific CNS tumors	492
Long-term effects of ALL therapy	436	Genetic syndromes related to brain tumors	503
Future drugs in ALL therapy	436	Further reading and references	504
Further reading and references	437		
		23. Neuroblastoma	507
19. Acute myeloid leukemia	439	JULIE KRYSTAL, ELIZABETH SOKOL AND ROCHELLE BAGATELL	
ARLENE REDNER AND RACHEL KESSEL		Epidemiology	507
Incidence and epidemiology	439	Predisposition	507
Etiology and predisposing conditions	439	Pathology and biology	507
Clinical features	440	Clinical features	508
Diagnostic and monitoring studies	441	Diagnosis and staging	510
Classification of AML	442	Treatment modalities	511
Supportive care	447	Prognosis, risk stratification, and therapy	513
The treatment of newly diagnosed AML	448	Neuroblastoma in the adolescent and young adult	522
Prognosis of newly diagnosed AML	450	Further reading and references	522
Relapsed and refractory AML	450		
Novel therapeutic approaches	451	24. Renal tumors	525
Acute promyelocytic leukemia	454	ANNE B. WARWICK AND JEFFREY S. DOME	
AML special subgroups	456	Wilms tumor	525
Further reading and references	457	Nephroblastomatosis	538
		Congenital mesoblastic nephroma	538
20. Hodgkin lymphoma	459	Clear cell sarcoma of the kidney	539
CHRISTINE M. SMITH AND DEBRA L. FRIEDMAN		Rhabdoid tumor of the kidney	539
Etiology and epidemiology	459	Renal cell carcinoma	539
Risk factors	459	Further reading and references	540
Biology	460		
Pathology	460	25. Rhabdomyosarcoma and other soft-tissue sarcomas	541
Clinical presentation	461	SEEMA AMIN AND CAROLYN FEIN LEVY	
Diagnostic evaluation and staging	464	Incidence and epidemiology	541
Prognostic factors	465	Pathologic and genetic classification	542
Treatment	466	Clinical features	545
Follow-up evaluations	471	Diagnostic evaluation	547
Further reading and references	471	Staging	549
Web resources	472	Prognosis	551
		Treatment	552
21. Non-Hodgkin lymphoma	473	Follow-up after completion of therapy	558
MARY S. HUANG AND HOWARD J. WEINSTEIN		Recurrent disease	559
Introduction	473	Future perspectives	560
Incidence and epidemiology	473	Further reading and references	561
Pathologic classification	474		
Clinical features	475		
Diagnosis	475		

26. Malignant bone tumors	563	30. Hematopoietic stem cell transplantation and cellular therapy	623
KATRINA WINSNES AND NOAH FEDERMAN		HISHAM ABDEL-AZIM AND MICHAEL A. PULSIPHER	
Osteosarcoma	563	Allogeneic stem cell transplantation	623
Ewing sarcoma family of tumors	572	HSC sources, collection, and manipulation	628
Other bone tumors	578	Graft manipulation postcollection	630
Further reading and references	581	Medical evaluation of HSC donors	630
27. Retinoblastoma	583	Pretransplantation preparative regimens (conditioning)	631
AMISH SHAH AND ANN LEAHEY		Engraftment	635
Incidence	583	Complications of HSCT	636
Classification	583	Recent advances in HSCT	652
Risk for second malignant neoplasms	585	Outcomes	655
Pathology	586	Further reading and references	657
Clinical features	586	31. Management of oncologic emergencies	659
Differential diagnosis	587	JASON L. FREEDMAN, CAITLIN W. ELGARTEN AND SUSAN R. RHEINGOLD	
Patterns of spread	587	Metabolic emergencies	659
Diagnostic procedures	588	Cardiothoracic emergencies	663
Classification	588	Abdominal emergencies	664
Treatment	589	Renal emergencies	666
Treatment of intraocular RB	590	Neurologic emergencies	668
Treatment of recurrent RB	594	Endocrine emergencies	669
Treatment of extraocular RB	594	Treatment-associated emergencies	671
Posttreatment management	594	Further reading and references	673
Further reading and references	595	32. Supportive care of patients with cancer	675
28. Extracranial germ cell tumors	597	ANURAG K. AGRAWAL AND JAMES FEUSNER	
ADRIANA FONSECA AND THOMAS A. OLSON		Management of infectious complications	675
Epidemiology	597	Recognition and management of nausea and vomiting	686
Biology	597	Mucositis	688
Histology	597	Pain management	690
Molecular characteristics	598	Nutritional status of the oncology patient	696
Clinical features	599	Utilization of hematopoietic growth factors	698
Diagnostic evaluation	600	Management of acute radiation side effects	700
Staging and risk stratification	601	Management of CVCs	703
Treatment	601	Posttreatment immunizations	708
Risk-stratified therapeutic approaches	607	Palliative care	709
Relapsed and resistant germ cell tumors	610	Further reading and references	710
Further reading and references	610	33. Evaluation, investigations, and management of late effects of childhood cancer	713
29. Hepatic tumors	613	MIRIAM RADINSKY AND JONATHAN D. FISH	
KATHRYN S. SUTTON AND THOMAS A. OLSON		Models of survivorship care	713
Incidence	613	Interventions and screening guidelines	714
Epidemiology	613	Organ system—specific late effects	716
Pathology	615	Future considerations	733
Clinical features	615	Further reading and references	733
Diagnostic evaluation	615		
Staging and risk stratification	617		
Treatment	618		
Further reading and references	620		

34. Psychosocial factors impacting children with cancer and their families 735
 AMY NADEL

Time of diagnosis 735
 Treatment initiation 740
 Illness stabilization 742
 During relapses and recurrences 743
 Treatment outcomes: the unsuccessful course 744
 Treatment outcomes: the successful course 746
 Conclusion 747
 Further reading and references 748

35. Pediatric blood banking principles and transfusion medicine practices 749
 MAHA AL-GHAFFRY AND CASSANDRA D. JOSEPHSON

Introduction 749
 Immunohematology 749

Donor recruitment and testing 750
 Blood collection and processing 751
 Blood products 753
 Blood component modification and administration 756
 Transfusion reactions 758
 Special populations 761
 Therapeutic apheresis 763
 Patient blood management 764
 Further reading and references 765

Appendix 1: Hematological reference values 767
Index 781

Maha Al-Ghaffry, Division of Pediatric Hematology/Oncology and Stem Cell Transplantation, Cohen Children's Medical Center, New Hyde Park, NY, United States; Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States

Carl E. Atlas, Pediatric Hematology-Oncology, Texas Children's Hospital/Baylor College of Medicine, Houston, TX, United States; Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States

Laura Arant, Division of Pediatric Hematology/Oncology and Stem Cell Transplantation, Cohen Children's Medical Center of New York, New Hyde Park, NY, United States; Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States

Mark P. Atlas, Division of Pediatric Hematology/Oncology and Stem Cell Transplantation, Cohen Children's Medical Center of New York, New Hyde Park, NY, United States; Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States

Rochelle Bagwell, Division of Oncology, Department of Pediatrics, The Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

Liabel Elenc, Division of Pediatric Hematology/Oncology and Stem Cell Transplantation, Cohen Children's Medical Center of New York, New Hyde Park, NY, United States; Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States; Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, NY, United States

Francine Gail, Vascular Anomalies Program, Lenox Hill Hospital, Northwest Health, New York, NY, United States

James B. Kaul, Division of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medical College, New York, NY, United States

Brian M. Delmonico, Division of Pediatric Hematology/Oncology and Stem Cell Transplantation, Cohen Children's Medical Center of New York, New Hyde Park, NY, United States; Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States

Olive S. Eckstein, Pediatric Hematology-Oncology, Texas Children's Hospital/Baylor College of Medicine, Houston, TX, United States; Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States

Caitlin W. Eganter, Department of Pediatrics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States; Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, United States

Mohamed Tarek Elgheitany, Departments of Pathology & Immunology and Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, United States

Nora Federman, Department of Pediatrics, Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States; Department of Orthopedics, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States; Department of Pediatric Bone and Soft Tissue Sarcoma Program, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, United States; Clinical & Translational Research Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States

Carolee Felix-Loy, Division of Pediatric Hematology/Oncology and Stem Cell Transplantation, Cohen Children's Medical Center of New York, New Hyde Park, NY, United States; Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States

John Frazier, Department of Pediatrics, Division of Oncology, UCSF Benioff Children's Hospital, Oakland, CA, United States